Evidence map›Paper›PMID 42153509›Full record

ArticleCell proliferation2026

Oxidative Stress Drives Cell Cycle Stalling, Apoptosis and Metabolic Suppression in Cystatin B Deficient EPM1 Patient iPSCs.

Shekhar Singh, Lidiia Plotnikova, Teemu Tiukuvaara, Reetta Kälviäinen, Riikka H Hämäläinen

Abstract read
In one paragraph

Article in Cell proliferation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shekhar SinghA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Lidiia PlotnikovaA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Teemu TiukuvaaraA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Reetta KälviäinenEpilepsy Center, Kuopio University Hospital, Member of the European Reference Network, EpiCARE, Kuopio, Finland.ORCID https://orcid.org/0000-0003-2935-5131
Riikka H HämäläinenA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.ORCID https://orcid.org/0000-0002-5102-0672

Funding

Horizon 2020 Framework Programme 101034307Itä-Suomen Yliopisto
6 · The paper itself

Abstract

Cystatin B (CSTB) is an inhibitor of cysteine proteases, particularly cathepsins. Biallelic loss-of-function mutations in the CSTB gene are causative for progressive myoclonic epilepsy type 1 (EPM1), a neurodegenerative disorder characterised by stimulus-sensitive myoclonus and generalised tonic-clonic seizures. Pathomechanisms underlying the disease progression include disturbed proteostasis, increased oxidative stress, neuroinflammation and increased neuronal apoptosis. CSTB downregulation can also lead to cell cycle defects and reduced cell proliferation. Conversely, overexpression of CSTB has been reported to drive proliferation and survival of cancer cells, emphasising the important role of CSTB in cell growth and survival. In the current study, we focused on the role of CSTB in regulating proliferation and survival of EPM1 patients' stem cells. We reprogrammed EPM1 patient fibroblasts into induced pluripotent stem cells (iPSCs), a highly proliferative cell type. Patient cells manifested poor growth and increased apoptosis. Further, EPM1 cells showed oxidative stress, increased lysosomal activity, increased DNA damage and suppressed metabolism. Treatment with antioxidants rescued the growth phenotype and activated metabolism, suggesting oxidative stress as the cause and suppressed metabolism as a protective response. Our data strengthen the central role of CSTB in supporting cell survival and growth. Elucidating the regulatory role of CSTB expression in cell growth can advance our understanding of the pathophysiological mechanisms underlying both EPM1 and cancer and could inform the development of novel therapeutic strategies.

Indexed as

apoptosiscell cyclescystatin BDNA damageEPM1metabolismproliferation

Identifiers

PMID42153509
PMCPMC13325810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.